Document:

Exhibit
10.68

 

NOTE
PURCHASE AGREEMENT

 

This
NOTE PURCHASE AGREEMENT (this “Agreement”) is dated as of                     , 2021 and is made by and between Bioxytran,
Inc., a Nevada corporation (the “Company”), and the investors named on the signature pages hereto (the “Investors”).

 

WHEREAS,
the Company has offered to certain accredited investors (as defined in Regulation D under the Securities Act of 1933, as amended)
the Company’s Convertible Notes (the “Notes”);

 

WHEREAS,
each Investor has agreed pursuant to such Principal Balance of Notes set forth therein in accordance with the terms, subject
to the conditions, and in reliance on, the recitals, representations, warranties, covenants and agreements set forth herein.

 

NOW
THEREFORE, in consideration of the mutual covenants, conditions and agreements herein contained, the receipt and sufficiency
of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

1.          
Purchase and Sale of Notes. Subject to the terms and conditions set forth in this Section 1 and elsewhere in this Agreement,
each Investor has agreed to purchase from the Company, and the Company has agreed to sell to such Investor, at the Closing (as
defined below) the Principal Balance of Notes set forth on the Investor’s signature page.

 

2.          
Closing; Deliveries. Subject to the satisfaction of the initial closing conditions (as set forth below), the initial closing
(the “Initial Closing”) of the purchase and sale of the Notes shall take place on the date hereof. At one or
more subsequent closings (each, a “Subsequent Closing,” and together with the Initial Closing, a “Closing”),
the Company may sell additional Notes to additional Investors.

 

At
each Closing, (i) each Investor who shall purchase Notes hereunder shall deliver or shall have previously delivered to the Company
cash, wire transfer or a certified check in an amount equal to 100% of the principal amount subscribed for by such Investor, together
with an executed signature page to this Agreement, and (ii) the Company shall issue and deliver to each Investor an executed Note
in the Principal Balance purchased by such Investor in substantially the form set forth at Exhibit A hereto. Each Closing
shall take place at the principal executive offices of the Company or at such other place or time as the Company may specify.

 

3.          
Representations, Warranties and Covenants of Company. The Company represents and warrants to the Investors that as of the
date hereof:

 

a.          
Corporate Existence and Power. (i) The Company is a corporation, duly organized, validly existing and in good standing
under the laws of the state of Delaware; (ii) the Company has the power and authority to conduct its business in the manner in
which it is currently being conducted; and (iii) the Company has the power and authority to execute, deliver and perform this
Agreement and the Notes (collectively, the “Transaction Documents”) and to sell and issue the Notes hereunder.

 

     

     

    

 

b.          
Valid and Binding Agreement. The execution, delivery and performance of each Transaction Document have been duly authorized
by all requisite action of the Company, and each Transaction Document constitutes a valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms. The execution, delivery and performance of this Agreement and the
other Transaction Documents by the Company does not and, to the knowledge of the Company, will not: (i) conflict with, or violate
any provision of, statute, law, rule, regulation, order, judgment, injunction, decree or award of any arbitrator or governmental
authority having applicability to the Company or its business, assets, or properties, or any provision of its certificate of incorporation,
bylaws or similar governing instruments or (ii) conflict with, violate, or result in any breach of, or constitute a default under,
any agreement or instrument to which the Company is now a party or by which the Company or any of its properties or assets may
be bound or affected.

 

		4.	Representations
and Warranties of the Investors.

 

a.   
Purchase Entirely for Own Account. The Investor acknowledges that this Note is made with the Investor in reliance upon
the Investor’s representation to the Company, which the Investor hereby confirms by executing this Note, that this Note
and the Conversion Shares (collectively, the “Securities”) will be acquired for investment for the Investor’s
own account, not as a nominee or agent (unless otherwise specified on the Investor’s signature page hereto), and not with
a view to the resale or distribution of any part thereof, and that the Investor has no present intention of selling, granting
any participation in, or otherwise distributing the same. By executing this Note, the Investor further represents that the Investor
does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to
such person or to any third person, with respect to the Securities. If other than an individual, the Investor also represents
it has not been organized solely for the purpose of acquiring the Securities.

 

b.   
Disclosure of Information; Non-Reliance. The Investor acknowledges that it has received all the information it considers
necessary or appropriate to enable it to make an informed decision concerning an investment in the Securities. The Investor further
represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions
of the offering of the Securities. The Investor confirms that the Company has not given any guarantee or representation as to
the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment
in the Securities. In deciding to purchase the Securities, the Investor is not relying on the advice or recommendations of the
Company and has made its own independent decision that the investment in the Securities is suitable and appropriate for the Investor.
The Investor understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities
or made any finding or determination concerning the fairness or advisability of this investment.

 

c.  
Investment Experience. The Investor is an investor in securities of companies in the development stage and acknowledges
that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial
or business matters that it is capable of evaluating the merits and risks of the investment in the Securities.

 

     

     

    

 

d.   Accredited
Investor. The Investor is an “accredited investor” within the meaning of Regulation D promulgated under the
Securities Act. The Investor agrees to furnish any additional information requested by the Company or any of its
affiliates to assure compliance with applicable U.S. federal and state securities laws in connection with the purchase and
sale of the Securities.

 

e.  
Restricted Securities. The Investor understands that the Securities have not been, and will not be, registered under the
Securities Act or state securities laws, by reason of specific exemptions from the registration provisions thereof which depend
upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations
as expressed herein. The Investor understands that the Securities are “restricted securities” under U.S. federal and
applicable state securities laws and that, pursuant to these laws, the Investor must hold the Securities indefinitely unless they
are registered with the Securities and Exchange Commission and registered or qualified by state authorities, or an exemption from
such registration and qualification requirements is available. The Investor acknowledges that the Company has no obligation to
register or qualify the Securities for resale and further acknowledges that, if an exemption from registration or qualification
is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding
period for the Securities, and on requirements relating to the Company which are outside of the Investor’s control, and
which the Company is under no obligation, and may not be able, to satisfy.

 

f. 
No Public Market. The Investor understands that no public market now exists for the Securities and that the Company has
made no assurances that a public market will ever exist for the Securities.

 

g.  
No General Solicitation. The Investor, and its officers, directors, employees, agents, stockholders or partners have not
either directly or indirectly, including through a broker or finder solicited offers for or offered or sold the Securities by
means of any form of general solicitation or general advertising within the meaning of Rule 502 of Regulation D under the Securities
Act or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act. The Investor acknowledges
that neither the Company nor any other person offered to sell the Securities to it by means of any form of general solicitation
or advertising within the meaning of Rule 502 of Regulation D under the Securities Act or in any manner involving a public offering
within the meaning of Section 4(a)(2) of the Securities Act.

 

5.           
Limitations on Disposition. Without in any way limiting the representations set forth above, each Investor agrees not to
make any disposition of all or any portion of the applicable Notes unless and until (i) there is then in effect an effective registration
statement under the Securities Act of 1933, as amended (the “Securities Act”), covering such proposed disposition
and such disposition is made in accordance with such registration statement; or (ii) an exemption to registration under the Securities
Act and applicable state securities laws is available. Each Investor further understands and agrees that, until so registered
or transferred pursuant to the provisions of Rule 144 under the Securities Act, the Notes, whether upon initial issuance or upon
any transfer thereof, shall bear a legend, prominently stamped or printed thereon, reading substantially as follows:

 

“THIS
SECURITY HAS NOT BEEN REGISTERED, AND THE ISSUER HEREOF DOES NOT INTEND TO REGISTER THIS SECURITY, UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”) OR

 

     

     

    

 

THE
SECURITIES OR BLUE SKY LAWS OF ANY STATE AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
LAWS AND, IF REQUESTED BY THE ISSUER HEREOF, UPON DELIVERY TO THE ISSUER HEREOF OF AN OPINION OF COUNSEL (SATISFACTORY TO THE
ISSUER HEREOF) TO THE EFFECT THAT SUCH TRANSFER IS EXEMPT FROM REGISTRATION UNDER (OR OTHERWISE IN COMPLIANCE WITH) THE SECURITIES
ACT AND APPLICABLE STATE SECURITIES LAW.

 

THE
ISSUER OF THIS SECURITY IS NOT OBLIGATED TO RECOGNIZE ANY SALE OR OTHER TRANSFER OF THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN
MADE OTHER THAN IN ACCORDANCE WITH THE PREVIOUS PARAGRAPH. IF A SALE OR TRANSFER OF THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN
IS MADE IN CONTRAVENTION OF THE PRECEDING PARAGRAPH, THE ISSUER OF THIS SECURITY MAY REQUIRE SUCH TRANSFEREE TO TRANSFER THIS
SECURITY OR THE APPLICABLE BENEFICIAL INTEREST HEREIN TO A PERSON THAT WOULD HAVE BEEN A PERMITTED TRANSFEREE OF SUCH TRANSFEREE’S
TRANSFEROR. IF THE OBLIGATION TO TRANSFER DESCRIBED IN THE PRECEDING SENTENCE IS NOT MET, THE ISSUER HEREOF IS IRREVOCABLY AUTHORIZED,
WITHOUT ANY OBLIGATION, TO TRANSFER THIS SECURITY OR THE APPLICABLE BENEFICIAL INTEREST HEREIN IN A MANNER CONSISTENT WITH THE
RESTRICTIONS SET FORTH IN THIS PARAGRAPH AND, IF THIS SECURITY OR SUCH BENEFICIAL INTEREST HEREIN IS SOLD, THE ISSUER HEREOF SHALL
DISTRIBUTE THE NET PROCEEDS OF SUCH SALE TO THE ENTITLED PERSON.

 

THIS
SECURITY IS NOT A DEPOSIT, BANK ACCOUNT OR OBLIGATION OF ANY BANK. THIS SECURITY IS NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE
CORPORATION OR ANY OTHER AGENCY, AND IS SUBJECT TO INVESTMENT RISK, INCLUDING POSSIBLE LOSS OF PRINCIPAL.”

 

		6.	Miscellaneous.

 

a. 
Successors and Assigns. Except as otherwise provided in this Agreement, the terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
or obligations under or by reason of this Agreement, except as expressly provided herein.

 

b. 
Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware without regard
to conflict of laws principles.

 

     

     

    

 

c.  
Counterparts; Signatures. This Agreement is intended to be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterpart signature pages to this
Agreement may be delivered by Docusign, .pdf and/or electronic transmission.

 

d.  
Notices. Unless otherwise provided, any notice, request, or other communication shall in writing and shall be given by
personal delivery, national overnight courier, by certified or registered United States mail, postage prepaid to the addresses
or to the email address set forth on the signature page hereof. In case of service by mail, notices shall be deemed complete at
the expiration of the second business day after mailing.

 

e.  
Amendments and Waivers. Except as otherwise provided herein, any term of this Agreement may be amended and the observance
of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively),
only with the written consent of the Company and the holders of at least 51% of the outstanding principal amount due under the
Notes. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any securities
purchased under this Agreement at the time outstanding, each future holder of all such securities, and the Company.

 

f.  
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded
and shall be enforceable in accordance with its terms.

 

g.  
Exculpation Among Investors. Each Investor acknowledges that such Investor is not relying upon any person, firm or corporation,
other than the Company and its officers and directors, in making its investment or decision to invest in the Company. Each Investor
agrees that no other Investor, nor the respective controlling persons, officers, directors, partners, agents or employees of any
other Investor shall be liable for any action heretofore or hereafter taken or omitted to be taken by any of them in connection
with sale, issuance and enforcement of the Notes.

 

h.  
Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties
and no party shall be liable or bound to any other party in any manner by any warranty, representation, or covenant except as
specifically set forth herein.

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Note Purchase Agreement as of the date first above written.

 

Bioxytran,
Inc.

 

	By:	 	 

 

     

     

    

 

The
undersigned hereby acknowledges and agrees to become party to and to succeed to all of the rights and obligations of an “Investor”
under the Note Purchase Agreement. By execution hereof, the undersigned hereby authorizes the Company to append this signature
page as a counterpart signature page to the Note Purchase Agreement.

 

PRINCIPAL
BALANCE:                                                                                        
                                

 

INVESTOR:

 

Individual:

 

	 	 
	Print Name:	 
	 	 	 
	Entity:	 
	 	 	 
	 	 
	(name of entity)	 
	 	 	 
	By:	 	 
	Name:	 
	Title:	 
	 	 

Investor
Signature Page to Note Purchase AgreementExhibit 10.1

 

1847 HOLDINGS LLC

590 Madison Avenue, 21st Floor

New York, NY 10022

 

January 10, 2022

 

Mr. Eric Vandam

 

Dear Eric:

 

It is my privilege and pleasure to offer you the
position of Chief Operating Officer with 1847 Holdings LLC (the “Company”), subject to the terms herein. Your responsibilities
include overseeing the Company’s business operations and ensuring the Company has effective operational and financial procedures
in place. You will report directly to the Chief Executive Officer and establish policies that promote Company culture and vision through
its operations. You will also be responsible for the efficiency of the business, which includes maintaining control of diverse business
operations of the Company’s various subsidiaries. I am confident that your strategic vision, operational expertise and commitment
to our culture and values will be a tremendous asset to the executive leadership team and the organization. The details of your offer
are as follows:

 

		●	BASE SALARY. You will be entitled to an annual base salary of $300,000. The base salary will be paid by-weekly
with standard payroll deductions and less applicable taxes. The base salary will be reviewed annually as part of the performance review
process and the establishment of annual EBITDA budgets, and salary increases, if any, will be determined based on merit, performance,
additional/changing responsibilities and the Company’s financial health and performance.

 

		●	ANNUAL BONUS. You will be eligible for an annual bonus of up to 50% of your applicable base salary. You
will work with the board of directors of the Company to agree upon metrics in excess of present earnings targets to achieve maximum annual
bonus potential. You must be actively employed at the time of payment to receive this bonus.

 

		●	BENEFITS AND EQUITY INCENTIVES. You will be permitted, if and to the extent eligible, to participate in
all employee benefit plans, policies and practices now or hereafter maintained by or on behalf of the Company and the portfolio companies,
commensurate your position with the Company. The Company will provide paid medical insurance. If you do not qualify for the Company’s
medical insurance plan, or if you wish to get independent medical insurance, you will be reimbursed up to the amount the Company would
have paid for you to join the Company’s medical insurance plan. You will be permitted to participate in the Company’s equity
incentive plan when and if such plan is adopted by the board of directors of the Company at a level that is consistent with your position
with the Company. The determination of the equity award shall be in the discretion of the board of directors of the Company.

 

     

     

    

 

		●	VACATION. You will receive four weeks of vacation per calendar year and seven Company holidays per fiscal
year.

 

		●	SEVERANCE. If you are terminated by the Company without cause, you will be entitled, subject to your execution
of a release in form and substance acceptable to the Company, to 6 months of base compensation, which will be paid in lump sum within
two weeks of the separation date.

 

		●	PREVIOUS EMPLOYMENT. We expect you to observe any contractual or legal obligations that you owe to any
previous employer.  Please advise us of any restrictive covenants, non-solicitation covenants, or other contractual or legal obligations
you owe to your previous employer.

 

		●	CONFIDENTIALITY. You shall not, directly or indirectly, disclose to any person or entity who is not authorized
by the Company or any subsidiary or affiliate to receive such information, or use or appropriate for your own benefit or for the benefit
of any person or entity other than the Company or any subsidiary or affiliate, any documents or other papers relating to the Company’s
business or the customers of the Company or any subsidiary or affiliate, including, without limitation, files, business relationships
and accounts, pricing policies, customer lists, computer software and hardware, or any other materials relating to the Company’s
business or the customers of the Company or any affiliate of the Company or any trade secrets or confidential information, including,
without limitation, any business or operational methods, drawings, sketches, designs or product concepts, know-how, marketing plans or
strategies, product development techniques or plans, business acquisition plans, financial or other performance data, personnel and other
policies of the Company or any affiliate of the Company, whether generated by you or by any other person, except as required in the course
of performing your duties hereunder or with the express written consent of the Company; provided, however, that the confidential
information shall not include any information readily ascertainable from public or published information, or trade sources or independent
third parties (other than as a direct or indirect result of unauthorized disclosure by you). This confidentiality provision shall survive
the termination of this offer letter and the cessation of your employment.

 

		●	NON-COMPETITION. During your employment hereunder, you shall not engage, directly or indirectly, as an
employee, officer, director, partner, manager, consultant, agent, owner (other than a minority shareholder or other equity interest of
not more than 1% of a company whose equity interests are publicly traded on a nationally recognized stock exchange or over- the-counter)
or in any other capacity, in any business or entity that is in competition with the Company or any of its subsidiaries. Although the Company
understands that you may continue to provide limited consulting services or have a board seat on one or more other companies, you will
devote a significant majority of your work time to the Company and, in any event, a sufficient amount of your time to satisfactorily perform
all of your duties as Chief Operating Officer of the Company.

 

		●	NON-SOLICITATION. For a two-year period following the termination of your employment for any reason or
without reason, you shall not solicit or induce any person who was an employee of the Company or any of its subsidiaries or related companies
on the date of your termination or within three months prior to leaving your employment with the Company or any of its subsidiaries or
related companies to leave their employment with the Company or any of its subsidiaries or related companies.

 

    2

     

    

 

		●	CONTINGENT OFFER. This offer is contingent upon the favorable completion of a drug and alcohol screening,
background screening, and reference checks, along with proper documentation of your legal ability to work in the United States.  

 

		●	AT-WILL EMPLOYMENT. Your employment is at-will and will begin with the Company on a date mutually agreed
upon.

 

		●	RESIGNATION. You agree to provide the Company with 30 days’ notice prior to resigning from or otherwise
terminating your employment with the Company.

 

		●	SEVERABILITY; SPECIFIC PERFORMANCE: If any term or other provision of this offer letter is invalid, illegal,
or incapable of being enforced by any law or public policy, all other terms or provisions of this offer letter shall nevertheless remain
in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced,
the parties hereto shall negotiate in good faith to modify this offer letter so as to effectuate the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated
to the greatest extent possible. Each party acknowledges and agrees that a breach or threatened breach of this offer letter would cause
irreparable damage to the other party and that the injured party may not have an adequate remedy at law. Therefore, the obligations of
the parties under this offer letter shall be enforceable by a decree of specific performance issued by any court of competent jurisdiction,
and appropriate injunctive relief may be applied for and granted in connection therewith. Such remedies shall, however, be cumulative
and not exclusive and shall be in addition to any other remedies which any party may have under this offer letter or otherwise. The parties
further agree that, in the event of any action for specific performance in respect of such breach or violation by a party, the other party
will not assert the defense that a remedy at law would be adequate.

 

		●	MISCELLANEOUS: Facsimile execution and delivery of this offer letter is legal, valid and binding execution
and delivery for all purposes. This offer letter shall not confer any rights or remedies upon any person other than the parties and their
respective successors and permitted assigns. This offer letter constitutes the entire agreement among the parties and supersedes any prior
understandings, agreements, or representations by or among the parties, written or oral, to the extent they related in any way to the
subject matter hereof. This offer letter may be executed in one or more counterparts, each of which shall be deemed an original but all
of which together will constitute one and the same instrument. This offer letter shall be governed by and construed in accordance with
the laws of the State of New York without regard to principles of conflicts of laws. No amendment of any provision of this offer letter
shall be valid unless the same shall be in writing and signed by both of the parties hereto.

 

[Signature Page Follows]

 

    3

     

    

 

While every member of our team is critical to
our success, your role of Chief Operating Officer is one that I look to for significant contributions. I look forward to welcoming you
to the team, working with you and positioning the Company for a successful future! If you have any questions, please do not hesitate to
call me.

 

Regards,

 

	1847 Holdings LLC	 
	 	 	 
	/s/ Ellery Roberts	 
	Name:	Ellery Roberts	 
	Title:	Chief Executive Officer	 

 

	AGREED AND ACCEPTED:	 	 
	 	 	 
	/s/ Eric Vandam	 	1/10/22
	Eric Vandam	 	Date

 

Please return a signed copy of this offer letter
as formal acceptance of your ability to perform the requirements of the position. Your employment with the Company is considered “at
will” and can be terminated by you at any time. The Company also reserves the same right.

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]